Study guide
16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan
Key Takeaways Explain This Topic AI
Women experience major depressive disorder (MDD) at approximately twice the lifetime rate of men, with heightened vulnerability occurring during critical neuroendocrine transition windows including menarche, the luteal premenstrual phase, pregnancy, the postpartum period, and perimenopause.
Major Depressive Disorder diagnosis requires at least 5 of 9 DSM-5 SIGECAPS symptoms present nearly every day for at least 2 weeks, with at least one core symptom being depressed mood or anhedonia; universal screening utilizing the PHQ-2 and PHQ-9 facilitates early triage, and any affirmative response to item 9 mandates immediate clinical suicide risk assessment.
Premenstrual Dysphoric Disorder (PMDD) involves severe affective and somatic symptoms strictly limited to the luteal phase that remit rapidly following menses onset; first-line therapy includes lifestyle modifications and SSRIs, which demonstrate rapid efficacy when dosed either continuously or intermittently during the luteal phase only.
Untreated maternal depression during pregnancy carries grave obstetric and developmental risks (preterm delivery, fetal growth restriction, impaired maternal-infant bonding) that often outweigh medication risks; sertraline and escitalopram are preferred first-line agents in pregnancy and lactation, while paroxetine is avoided in early gestation due to congenital cardiac malformation concerns (ventricular and atrial septal defects).
First-line pharmacotherapy for depression and anxiety comprises SSRIs and SNRIs alongside evidence-based psychotherapies (Cognitive Behavioral Therapy and Interpersonal Therapy); clinicians must anticipate transient neonatal poor adaptation syndrome (NPAS) while reassuring patients that absolute risks of persistent pulmonary hypertension of the newborn (PPHN) remain low (<3 per 1,000).
Last updated: October 2026
Epidemiology & Neuroendocrine Vulnerability in Women
Depressive and anxiety disorders represent leading causes of disease burden and disability in women worldwide. Epidemiological data consistently demonstrate that women experience major depressive disorder (MDD) and generalized anxiety disorder (GAD) at approximately twice the lifetime rate of men (~21% lifetime prevalence in females vs. ~12% in males). This sex-based divergence emerges during adrenarche and puberty, persists throughout the reproductive years, and narrows somewhat following menopause, illustrating the powerful modulatory impact of gonadal steroid fluctuations on central neurotransmitter circuits.
Female affective vulnerability concentrates around specific neuroendocrine transition windows:
Menarche & Adolescence: Surging gonadal steroids interact with developing limbic and prefrontal circuits.
Premenstrual Phase (Late Luteal Phase): Abrupt post-ovulatory withdrawal of 17-beta estradiol and progesterone triggers affective symptoms in susceptible women.
Pregnancy & Postpartum: Marked supraphysiological elevations of circulating estrogens and progesterone plummet precipitously within hours of placental delivery, destabilizing central monoaminergic and gamma-aminobutyric acid (GABA) signaling.
Perimenopause: Erratic, fluctuating estradiol levels and progressive anovulation accelerate vulnerability to unipolar depression, even in women without prior psychiatric history.
At the cellular level, progesterone's neuroactive metabolite, allopregnanolone , functions as a potent positive allosteric modulator of GABA-A receptors. In susceptible individuals, maladaptive GABA-A receptor subunit plasticity impairs normal inhibitory tone during hormonal shifts. Furthermore, estradiol enhances serotonergic neurotransmission by upregulating tryptophan hydroxylase and modulating 5-HT1A and 5-HT2A receptor densities; rapid estradiol withdrawal destabilizes central serotonergic tone, precipitating depressive and anxiety phenotypes.
Major Depressive Disorder: DSM-5 Diagnostic Criteria & SIGECAPS
Under DSM-5 criteria, diagnosing Major Depressive Disorder requires at least 5 of the following 9 symptoms present nearly every day during the same 2-week period , representing a change from prior functioning. Crucially, at least one symptom must be depressed mood or loss of interest/pleasure (anhedonia) :
S — Sleep: Insomnia (initial, middle, or terminal) or hypersomnia nearly every day.
I — Interest: Markedly diminished interest or pleasure in all or almost all activities (anhedonia).
G — Guilt: Excessive, inappropriate, or delusional feelings of worthlessness or guilt.
E — Energy: Chronic anergia and persistent fatigue.
C — Concentration: Diminished ability to think, concentrate, or make decisions.
A — Appetite: Significant unintentional weight loss or gain (>5% change in a month), or daily appetite changes.
P — Psychomotor: Observable psychomotor agitation (restlessness) or retardation (slowed speech and movement).
S — Suicide: Recurrent thoughts of death, suicidal ideation with or without a plan, or suicide attempts.
Symptoms must cause clinically significant distress or functional impairment and cannot be attributable to a substance, medication, or medical condition (e.g., severe hypothyroidism or systemic lupus erythematosus).
Screening Instruments: PHQ-2, PHQ-9 & Suicide Risk Stratification
Universal depression screening is endorsed by ACOG and the USPSTF across adolescent, adult, pregnant, and postpartum encounters. Clinical practice relies on a validated two-stage screening cascade:
Patient Health Questionnaire-2 (PHQ-2): Evaluates anhedonia and depressed mood over the past 2 weeks (scored 0–6). A cutoff score ≥3 exhibits 83% sensitivity and 92% specificity for MDD, prompting immediate full PHQ-9 completion.
Patient Health Questionnaire-9 (PHQ-9): Assesses all 9 DSM-5 criteria (scored 0–27):
PHQ-9 Score Severity Recommended Clinical Management
1–4 Minimal / None Reassurance; routine rescreening.
5–9 Mild Watchful waiting, lifestyle optimization (sleep, exercise), rescreen in 4–8 weeks.
10–14 Moderate Formulate treatment plan: initiate psychotherapy (CBT/IPT) and/or SSRI pharmacotherapy.
15–19 Moderately Severe Prompt pharmacotherapy and/or structured psychotherapy; close clinical follow-up.
20–27 Severe Immediate combination pharmacotherapy and psychotherapy; urgent safety triage; psychiatric referral.
Important
Item 9 & Suicide Safety Triage: Any score >0 on Item 9 ("Thoughts that you would be better off dead, or of hurting yourself") mandates an immediate, comprehensive suicide risk assessment before the patient leaves the clinic . Evaluate active vs. passive ideation, presence of a specific lethal plan, intent, access to lethal means (firearms, stockpiled medications), prior suicide attempts, and protective factors. If active intent or plan with available means is identified, maintain continuous observation and arrange emergency psychiatric evaluation.
Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder (PMDD) affects 3% to 8% of reproductive-age women, characterized by severe affective and somatic symptoms that arise cyclically during the luteal phase (the 1–2 weeks preceding menses) and remit rapidly within a few days of menses onset, followed by a symptom-free follicular phase .
DSM-5 Criteria & Diagnosis
Diagnosis requires at least 5 symptoms during the week before menses across the majority of cycles in the past year. Crucially, at least 1 must be a core affective symptom :
Core Affective Symptoms: Marked affective lability (sudden crying spells, hypersensitivity), marked irritability or anger, markedly depressed mood or hopelessness, or marked anxiety/tension.
Additional Symptoms: Anhedonia, difficulty concentrating, lethargy, marked appetite changes/food cravings, hypersomnia or insomnia, feeling overwhelmed, and physical symptoms (breast tenderness, abdominal bloating, joint pain).
Prospective Confirmation: Symptoms must be prospectively verified using daily rating scales (e.g., Daily Record of Severity of Problems - DRSP) across at least two consecutive cycles to differentiate PMDD from premenstrual exacerbation of underlying MDD or GAD.
Management Strategies
Lifestyle Interventions: Aerobic exercise (≥150 min/week), stress reduction, sleep hygiene, calcium carbonate (1,200 mg/day), and vitamin B6 (pyridoxine 50–100 mg/day).
First-Line Pharmacotherapy (SSRIs): Sertraline (50–150 mg/day) and fluoxetine (20–40 mg/day) are first-line. Unlike MDD, PMDD responds rapidly to SSRIs within hours to days via rapid allopregnanolone/GABA-A receptor modulation. SSRIs can be administered continuously (daily throughout the month) or via luteal-phase dosing (initiated on cycle day 14 or ovulation and discontinued at menses onset), which yields equal efficacy while minimizing adverse effects like sexual dysfunction and weight gain.
Hormonal Suppression: Drospirenone-containing combined oral contraceptives (e.g., 3 mg drospirenone / 20 mcg ethinyl estradiol in a 24/4 regimen) are FDA-approved for PMDD, suppressing the hypothalamic-pituitary-ovarian axis. Refractory cases may require GnRH agonists (leuprolide) with estrogen/progestin add-back therapy.
Generalized Anxiety Disorder (GAD) & Panic Disorder
Generalized Anxiety Disorder (GAD): Excessive, uncontrollable worry across multiple domains for ≥6 months , associated with ≥3 somatic symptoms (restlessness, fatigue, poor concentration, irritability, muscle tension, sleep disturbance). Screened with the GAD-7 (cutoff ≥10 indicates clinically significant anxiety).
Panic Disorder: Recurrent, unexpected panic attacks featuring abrupt surges of intense fear peaking within minutes, accompanied by palpitations, sweating, dyspnea, choking sensation, chest pain, and persistent worry about subsequent attacks or behavioral avoidance.
Treatment: First-line pharmacotherapy comprises SSRIs and SNRIs combined with Cognitive Behavioral Therapy (CBT). Avoid chronic benzodiazepines due to tolerance, dependence, cognitive impairment, and neonatal floppy infant syndrome.
Pharmacotherapy Across the Female Lifespan
Medication Class Agent Dosing Range Key Clinical Pearls
SSRI Sertraline 25–200 mg daily First-line in pregnancy and lactation (lowest breast milk excretion); transient GI upset.
SSRI Escitalopram 10–20 mg daily Highly selective SERT inhibitor; low drug interaction potential; excellent perinatal safety.
SSRI Fluoxetine 10–60 mg daily Activating profile; long half-life (~7–14 days for norfluoxetine) prevents discontinuation syndrome; FDA-approved for PMDD.
SSRI Citalopram 10–40 mg daily Dose capped at 40 mg daily (20 mg if ≥60 years) due to dose-dependent QTc prolongation.
SSRI Paroxetine 10–50 mg daily Sedating, anticholinergic; high rates of weight gain and sexual dysfunction; avoid in pregnancy .
SNRI Venlafaxine 37.5–225 mg daily Dual 5-HT/NE reuptake inhibition; dose-dependent diastolic hypertension (monitor BP); severe withdrawal if missed.
SNRI Duloxetine 30–90 mg daily Efficacious for comorbid depression, fibromyalgia, and chronic neuropathic pain; monitor transaminases.
Adverse Effects & Discontinuation Syndrome
Common adverse effects include transient nausea, diarrhea, insomnia, headache, and long-term sexual dysfunction (anorgasmia, decreased libido in 30% to 50%). Abrupt cessation of short half-life agents (paroxetine, venlafaxine) causes Antidepressant Discontinuation Syndrome (FINISH mnemonic) : F lu-like symptoms, I nsomnia, N ausea, I mbalance (dizziness), S ensory disturbances ("brain zaps"), and H yperarousal. Always taper gradually over weeks to months.
Perinatal Psychopharmacology: Gestational & Lactational Safety
Clinicians must weigh the documented risks of medication exposure against the substantial hazards of untreated maternal illness :
Risks of Untreated Maternal Depression: Poor prenatal care, inadequate nutrition, increased substance use, preeclampsia, spontaneous preterm birth (<37 weeks), low birth weight (<2,500 g), impaired maternal-infant attachment, and maternal suicide.
Teratogenic Profiles: Sertraline and escitalopram are preferred in pregnancy. Large cohort registries demonstrate that SSRIs as a class do not increase the overall baseline risk of major congenital malformations (~3%). However, paroxetine is avoided in early pregnancy due to meta-analytic associations with congenital cardiac malformations, predominantly ventricular and atrial septal defects (VSD/ASD; odds ratio ~1.5 to 2.0).
Neonatal Poor Adaptation Syndrome (NPAS): Occurs in 15% to 30% of neonates exposed to SSRIs/SNRIs in late gestation. Manifests as self-limited jitteriness, irritability, weak cry, transient tachypnea, and mild hypoglycemia, resolving within 1 to 2 weeks with supportive care (skin-to-skin, swaddling).
Persistent Pulmonary Hypertension of the Newborn (PPHN): Late gestational SSRI exposure is associated with a tiny relative increase, but absolute risk remains extremely low (<3 per 1,000 live births) compared to the 1–2 per 1,000 baseline. Routine medication discontinuation prior to delivery is strictly discouraged , as maternal postpartum relapse rates exceed 60% to 70%.
Lactation: Sertraline has the lowest infant exposure (<1% of maternal weight-adjusted dose), making it the gold standard in breastfeeding. However, if a mother achieved remission on another agent during pregnancy, she should continue that effective medication postpartum.
Evidence-Based Psychotherapy Modalities
Cognitive Behavioral Therapy (CBT): First-line psychotherapy for mild-to-moderate depression, GAD, and panic disorder. Focuses on identifying and modifying cognitive distortions and integrating behavioral activation to overcome depressive withdrawal.
Interpersonal Therapy (IPT): Focuses on role transitions (e.g., transition to motherhood, menopause), interpersonal disputes, and grief/loss (pregnancy loss, infertility). Highly effective for perinatal mood disorders.